Immuron Limited revenue for the last year amounted to 3.18 M USD, the most of which — 3.21 M USD — came from its highest performing source at the moment, Hyper-immune Products, the year earlier bringing 1.21 M USD. The greatest contribution to the revenue figure was made by Australia — last year it brought Immuron Limited 2.45 M USD, and the year before that — 780.73 k USD.